Paper Details

  1. Home
  2. Paper Details

Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial.

Author: , BafadhelMona, Barra RibeiroLuciene, BitarãesCarina, BoulwareDavid R, ButlerChristopher, Campos SimplicioMaria Izabel, Cançado Monteiro SavassiLeonardo, Cruz MilagresAline, Diniz CallegariEduardo, Dos Santos Moreira SilvaEduardo Augusto, DybulMark, EzerNicole, FerreiraThiago Santiago, Figueiredo Guimaraes AlmeidaAna Paula, ForrestJamie I, GuoChristina M, GuyattGordon H, HarariOfir, LeeTodd C, McDonaldEmily Gibson, McKayPaula, Medeiros SilvaDaniela Carla, MillsEdward J, OliveiraRosemary, Quirino Dos SantosCastilho Vitor, RaynerCraig R, ReisGilmar, Ribeiro NogueiraAna Maria, Rodrigues SilvaJosue, RutonHinda, SpragueSheila, ThabaneLehana, WilsonLindsay A, de Figueiredo NetoAdhemar Dias, de Souza CamposVitoria Helena

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized controlled trial evaluated the efficacy of fluvoxamine plus inhaled budesonide for preventing disease progression in high-risk outpatients with early COVID-19. The study found that the combination treatment significantly reduced the incidence of severe disease requiring advanced care, with a probability of superiority of 98.7%. No significant differences were found between the groups for secondary outcomes. The study concluded that fluvoxamine plus inhaled budesonide is a promising treatment option for reducing severe COVID-19 in high-risk outpatients.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19. OBJECTIVE: To determine whether the combination of fluvoxamine and inhaled budesonide would increase treatment effects i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111398/

データ提供：米国国立医学図書館（NLM）

Combating COVID-19: A New Duo for Early Treatment

This [randomized platform trial] sheds light on the potential benefits of a combination therapy for [early-onset COVID-19]. The research investigates the efficacy of [oral fluvoxamine] and [inhaled budesonide] in a highly vaccinated population. The study aimed to determine if this combination would enhance treatment effects, providing a new approach for managing [COVID-19] in the era of widespread vaccination.

A Promising Combination for Mild COVID-19

The trial found that [oral fluvoxamine] plus [inhaled budesonide] significantly reduced the incidence of [severe disease requiring advanced care] in high-risk patients with [early COVID-19]. This suggests that this combination therapy could be a valuable tool in preventing disease progression and improving patient outcomes in the early stages of [COVID-19]. The study's results offer a positive note in the ongoing fight against this global pandemic.

A New Weapon in the Fight Against COVID-19

This study provides valuable insights into the potential benefits of a combination therapy for [early-onset COVID-19]. It's like a camel navigating a shifting sand dune, adapting to the evolving landscape of the pandemic. The research highlights the importance of exploring innovative treatment strategies to effectively combat [COVID-19], particularly in highly vaccinated populations. This study encourages further research into combination therapies for [COVID-19] and emphasizes the importance of proactive interventions in managing this challenging illness.

Dr.Camel's Conclusion

The study's findings offer a glimmer of hope in the fight against [COVID-19], suggesting that a combination of [oral fluvoxamine] and [inhaled budesonide] could be a valuable tool in preventing severe disease in high-risk patients. This research encourages further exploration of combination therapies and highlights the importance of continued vigilance and innovation in the face of this ongoing pandemic. As a camel adapts to the ever-changing desert landscape, we too must adapt and explore new solutions to combat this global health challenge.

Date :
  1. Date Completed 2023-05-17
  2. Date Revised 2023-05-25
Further Info :

Pubmed ID

37068273

DOI: Digital Object Identifier

PMC10111398

Related Literature

Article Analysis
・Effects of budesonide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.